Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
TEVA - Teva- Pharmaceutical Industries Ltd.
0.11(1.07%)9:00:02 PM 1/27/2023
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics

Stock news

    Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?

    Shareholders of Catalyst Pharmaceuticals (NASDAQ: CPRX) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries (NYSE: TEVA), was planning to make a generic version of its only marketed drug, Firdapse. With Catalyst's shares falling 30% in a day before slightly recovering, it's clear that the market is interpreting Teva's actions as severely threatening, and it's reasonable for investors to wonder if it's time to start looking for the door. Firs...

    Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More

    Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.

    Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025

    When the lights went out on 2022, all three major U.S. stock indexes had delivered their worst returns since 2008. While the Nasdaq losing a third of its value in such a short time frame is undoubtedly brutal for short-term traders, it represents a generational opportunity for patient investors to snag high-quality stocks at a discount. The first surefire bargain that has the potential to double your money by mid-decade is brand-name and generic-drug producer Teva Pharmaceutical Industries (NY...

    Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic

    Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.

    No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product

    Teva said Monday it plans to knock off Catalyst's only approved drug and CPRX stock — which has sat atop the IBD 50 for weeks — crashed.

    Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product

    Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a Notice Letter stating that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) submitted an abbreviated marketing application to the FDA for a generic version of Firdapse in the U.S. In the Notice Letter, Teva states that it intends to market a generic version of Firdapse before the expiration of Catalyst's patents covering U.S. patents expiring up to February 2037. Teva's Notice Letter states that its ANDA contains a Paragraph IV Certificat

    Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

    TEL AVIV, Israel, January 19, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint.

    3 Dirt Cheap Stocks to Buy in January

    While the stock market has performed abysmally over the past 12 months, there are plenty of stocks available at steep discounts. Three Motley Fool contributors were asked to identify dirt cheap stocks to buy in January. Here's why they chose Pfizer (NYSE: PFE), Teva Pharmaceutical Industries (NYSE: TEVA), and Vertex Pharmaceuticals (NASDAQ: VRTX).

    Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023

    TEL AVIV, Israel & PARSIPPANY, N.J., January 12, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2022 financial results, as well as on its financial guidance for 2023, on Wednesday, February 8, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

    TEVA Shares Rise on Broad Support for Opioids Settlement

    With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.